The Wall Street Journal recently highlighted Mercy as a national leader in expanding access to early cancer detection through precision medicine. The article focuses on a new wave of blood-based diagnostic tests that can detect dozens of cancers from a single vial of blood.
Mercy's Multi-Cancer Early Detection (MCED) test can detect more than 50 types of cancer, including aggressive, often fatal cancers. The earlier cancer is found, the better your odds are of surviving.
Under the guidance of Dr. Jay Carlson, medical director of oncology services, Mercy has administered more than 4,000 of these tests across its communities, offering treatment options when they’re most effective.
“These are the kinds of cancers that would otherwise go undetected until it’s too late,” Dr. Carlson said in the story.
Dr. Carlson recently testified at a U.S. House Ways & Means Health subcommittee hearing in Washington, D.C., where he shared how precision medicine and early detection are shaping the future of patient care.
The MCED test, which should be used together with annual cancer screenings, looks for signals in the bloodstream that may be linked to cancer. If a cancer signal is found, your care team will discuss next steps for treatment or recommend additional testing.
Read the full Wall Street Journal article here.
